

HR 2069

SPIKE Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 3, 2019

Current Status: Subcommittee Hearings Held.

Latest Action: Subcommittee Hearings Held. (May 21, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2069>

Sponsor

Name: Rep. Horsford, Steven [D-NV-4]

Party: Democratic • **State:** NV • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Reed, Tom [R-NY-23]	R · NY		Apr 3, 2019
Rep. Cox, TJ [D-CA-21]	D · CA		Apr 8, 2019
Rep. Wild, Susan [D-PA-7]	D · PA		Apr 8, 2019
Rep. Case, Ed [D-HI-1]	D · HI		Apr 30, 2019
Rep. Houlahan, Chrissy [D-PA-6]	D · PA		Apr 30, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Apr 30, 2019
Rep. Spanberger, Abigail Davis [D-VA-7]	D · VA		May 2, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		May 20, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		May 20, 2019
Rep. Steil, Bryan [R-WI-1]	R · WI		Nov 18, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Hearings By (subcommittee)	May 21, 2019
Ways and Means Committee	House	Referred to	Apr 3, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 2113	Related bill	Dec 24, 2020: Placed on the Union Calendar, Calendar No. 571.

Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act or the SPIKE Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties. The bill's requirements do not apply to low-cost drugs, as identified by the CMS.

Actions Timeline

- **May 21, 2019:** Subcommittee Hearings Held.
- **Apr 4, 2019:** Referred to the Subcommittee on Health.
- **Apr 3, 2019:** Introduced in House
- **Apr 3, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 3, 2019:** Referred to the Subcommittee on Health.